Platinum drugs are off the shortage list, but the underlying problem is unsolved FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Ready or not, AI-based decision support tools are entering oncology clinics
Regulators and health systems must adapt

Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.

November 15, 2024

FDA approves Aucatzyl for adults with r/r B-cell precursor ALL

FDA approved Aucatzyl (obecabtagene autoleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

November 15, 2024

Vol.50 No.43

Drugs & Targets

FDA approves MI Cancer Seek as a CDx test for adults and pediatric patients

FDA has approved MI Cancer Seek for use as a companion diagnostic to identify patients with cancer who may benefit from treatment with targeted therapies.

November 08, 2024

Vol.50 No.42

Regulatory News

At his 25-year “anniversary party,” Pazdur invites Califf and past FDA commissioners to talk about political interference

FDA’s cancer czar Richard Pazdur had a “silver anniversary” at the agency recently. So, he invited some guests—the commissioners he had reported to under the Democratic and Republican administrations.

November 01, 2024

Vol.50 No.41

By Claire Marie Porter

Regulatory News

FDA extends shelf-life for IV fluids in shortage after Hurricane Helene

More than a month has passed since Hurricane Helene took out Baxter North Cove plant, which manufactured 1.5 million IV fluid bags per day, supplying 60% of the intravenous solutions nationwide.

November 01, 2024

Vol.50 No.41

By Claire Marie Porter

Drugs & Targets

FDA approves Scemblix for newly diagnosed CML patients

Scemblix (asciminib) was granted accelerated approval by FDA for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

November 01, 2024

Vol.50 No.41

Platinum drugs are off the shortage list, but the underlying problem is unsolved

FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

YOU MAY BE INTERESTED IN

Ready or not, AI-based decision support tools are entering oncology clinics
Regulators and health systems must adapt

FDA approves Aucatzyl for adults with r/r B-cell precursor ALL

FDA approves MI Cancer Seek as a CDx test for adults and pediatric patients

At his 25-year “anniversary party,” Pazdur invites Califf and past FDA commissioners to talk about political interference

FDA extends shelf-life for IV fluids in shortage after Hurricane Helene

FDA approves Scemblix for newly diagnosed CML patients

Renew today!

Subscriber content

Never miss an issue!

Login

Platinum drugs are off the shortage list, but the underlying problem is unsolved

FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

YOU MAY BE INTERESTED IN

Ready or not, AI-based decision support tools are entering oncology clinicsRegulators and health systems must adapt

FDA approves Aucatzyl for adults with r/r B-cell precursor ALL

FDA approves MI Cancer Seek as a CDx test for adults and pediatric patients

At his 25-year “anniversary party,” Pazdur invites Califf and past FDA commissioners to talk about political interference

FDA extends shelf-life for IV fluids in shortage after Hurricane Helene

FDA approves Scemblix for newly diagnosed CML patients

Never miss an issue!

Login

Ready or not, AI-based decision support tools are entering oncology clinics
Regulators and health systems must adapt